Literature DB >> 27960613

Prevalence, clinical characteristics and echocardiography parameters of non-resistant, resistant and refractory hypertension in Chinese.

Gaozhen Cao1, Cong Chen1, Qingshan Lin2, Yan Chen3, Zhe Zhen3, Yuan Zou3, Juhua Liu3, Min Wu1, Run Wang1, Mingya Liu1, Chunting Zhao1, Shukun Lu2, Ming-Yen Ng2, Hung-Fat Tse1,3, Kai-Hang Yiu1,3.   

Abstract

OBJECTIVES: Refractory and resistant hypertension is defined as hypertension that is uncontrolled despite the use of multiple antihypertensives. The aim of the present study is to evaluate the prevalence, both in young and elderly, and the pattern of left ventricular hypertrophy (LVH) in South-Eastern Chinese patients with refractory, resistant and non-resistant hypertension.
METHODS: A total of 1455 patients (age 60.3 ± 13.9, male 55.7%) with essential hypertension were recruited. Refractory hypertension was defined as uncontrolled blood pressure (systolic/diastolic, ≥140/90 mm Hg) on ≥5 antihypertensive drug classes. Resistant hypertension was defined as uncontrolled blood pressure (systolic/diastolic, ≥140/90 mm Hg) on 3 or <140/90 mm Hg on ≥4 antihypertensive classes.
RESULTS: Among the total population, 1273 (87.4%) patients were considered non-resistant hypertension; 170 (11.7%) with resistant hypertension and 12 (0.8%) with refractory hypertension. The prevalence of the three groups of hypertension were similar between patients age <60 or ≥60. Patients with refractory hypertension had the most dilated LV dimension, greatest left ventricular mass index and highest prevalence of diastolic dysfunction than patients with resistant and non-resistant hypertension. In particular, all patients with refractory hypertension had either concentric or eccentric LVH.
CONCLUSIONS: In South-Eastern Chinese patients, the prevalence of refractory and resistant hypertension was 0.8% and 11.7%, respectively. Furthermore, no difference was observed in the hypertensive patterns between patients age <60 and ≥60. Importantly, patients with refractory hypertension had the worst LV remodeling with all suffering from either concentric or eccentric hypertrophy.

Entities:  

Keywords:  Resistant hypertension; echocardiography parameters; prevalence in South-Eastern Chinese; refractory hypertension

Mesh:

Substances:

Year:  2016        PMID: 27960613     DOI: 10.1080/00325481.2017.1272398

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  6 in total

1.  Frequency and factors linked to refractory hypertension among stroke survivors in Ghana.

Authors:  Fred Stephen Sarfo; John Akassi; Sheila Adamu; Vida Obese; Manolo Agbenorku; Bruce Ovbiagele
Journal:  J Neurol Sci       Date:  2020-06-05       Impact factor: 3.181

2.  Untreated Obstructive Sleep Apnea Is Associated With Myocardial Injury Independent of Blood Pressure Control in Hypertension.

Authors:  Macy M S Lui; H F Tse; Judith C W Mak; David C L Lam; Carmen W S Chan; Peony W C Chong; Mary S M Ip
Journal:  J Clin Sleep Med       Date:  2018-11-15       Impact factor: 4.062

Review 3.  Treatment of Resistant and Refractory Hypertension.

Authors:  Maria Czarina Acelajado; Zachary H Hughes; Suzanne Oparil; David A Calhoun
Journal:  Circ Res       Date:  2019-03-29       Impact factor: 17.367

4.  Refractory Hypertension: a Narrative Systematic Review with Emphasis on Prognosis.

Authors:  Giovanna Bacan; Angélica Ribeiro-Silva; Vinicius A S Oliveira; Claudia R L Cardoso; Gil F Salles
Journal:  Curr Hypertens Rep       Date:  2022-02-02       Impact factor: 5.369

5.  Associations of Echocardiography Markers and Vascular Brain Lesions: The ARIC Study.

Authors:  Michelle C Johansen; Amil M Shah; Seth T Lirette; Michael Griswold; Thomas H Mosley; Scott D Solomon; Rebecca F Gottesman
Journal:  J Am Heart Assoc       Date:  2018-12-18       Impact factor: 5.501

6.  The prevalence and predictors of resistant hypertension in high-risk overweight and obese patients: A cross-sectional study based on the 2017 ACC/AHA guidelines.

Authors:  Faris Haddadin; Karan Sud; Alba Munoz Estrella; Sananda Moctezuma; Lingling Wu; Joshua Berookhim; Claire Huang Lucas; Dipal Patel; Edgar Argulian
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-08-26       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.